The China Pulmonary Thromboembolism Registry Study (CURES)

China-Japan Friendship Hospital

Status: Enrolling

Conditions: Venous Thromboembolism; Pulmonary Embolism; Deep Venous Thrombosis

Treatments: Other: No intervention

Study type: Observational

Funder types: Other

Identifiers

NCT02943343

2016YFC0905600

Details and patient eligibility

About

Epidemiological data on pulmonary embolism (PE) in China needs to be updated and reported. The China Pulmonary Thromboembolism Registry Study (CURES) is designed to provide the cross-sectional spectrum and chronological trends of PE in China, as well as to reveal the intrinsic etiology and pathogenesis of the disease. The CURES is an ongoing large prospective multicenter registry, which was originally initiated in January 2009 via enrolling suspected or confirmed PE or PE with DVT (deep venous thrombosis) patients and assessed their in-hospital outcomes from 100 medical centers in the China PE-DVT network. As of July 2011, in order to determine the PE-relevant short-term outcomes, enrolled participants were followed-up for at least three months in a longitudinal manner. Since August 2016, with the launch and development of precision medicine research scheme in China, the main principle investigators of CURES decided to collect enrolled patients' blood samples with regular follow-ups every three or six months for at least two years (for long-term outcomes). The study protocol has been approved by the China-Japan Friendship Hospital ethics committee, and all collaborating centers received approvals from their local ethics committee. All patients provided written or verbal informed consent to their participation.

Enrollment: 15,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Patients aged 18 years or above who are admitted to the 100 participating medical centers with suspected PE or PE with DVT are potentially eligible participants and consecutively enrolled in this registry.

Inclusion criteria:

• Objectively confirmed symptomatic PE or PE with DVT patients aged 18 years or above;
• Be able to provide written or verbal informed consent to participation.

Exclusion criteria:

• Younger than 18 years;
• Participation in a therapeutic clinical trial with an unknown drug;
• Inability for at least three-month follow-up since July 2011;
• Suspected PE or PE with DVT patients admitted to the hospital whereas without confirmed medical evidence;
• Patients with a history of PE or DVT readmitted to the hospital for examination or treatment however with no evidence of acute episode or recurrence;
• Withdrawal or lack of informed consent.